摘要
目的:探讨中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对初治前弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)患者预后的意义。方法:回顾性分析2010年1月至2019年10月,新疆医科大学附属肿瘤医院收治的165例初治DLBCL患者,确定了NLR(>2.77)在预后预测中的最佳临界值,采用Log-rank检验和Cox回归模型进行分析,评价治疗前NLR对无进展生存期(progression free survival time,PFS)和总生存期(overall survival rate,OS)的影响。结果:在入选的165例患者中,有67例患者治疗前NLR升高(>2.77),NLR升高与PFS和OS较短的患者明显相关(P<0.001和P=0.003)。多变量分析进一步表明,NLR>2.77是PFS的独立预测因子。结论:治疗前NLR升高提示DLBCL患者预后不良。
Objective:The purpose of this study was to investigate the prognostic value of neutrophil to lymphocyte ratio(NLR)in patients with diffuse large B cell lymphoma(DLBCL)before treatment.Methods:From January 2010 to October 2019,165 patients with newly diagnosed DLBCL admitted to the Cancer Hospital Affiliated to Xinjiang Medical University were analyzed retrospectively,and the optimal critical value of NLR(>2.77)in prognosis prediction was determined,Log-rank test and Cox Regression model were used to evaluate the effect of NLR on OS and PFS before treatment.Results:The 165 selected patients,NLR was increased in 67 patients(>2.77)before treatment,and NLR was significantly correlated with PFS and OS shorter patients(P<0.001 and P=0.003).Multivariate analysis further showed that NLR>2.77 was an independent predictor of PFS.Conclusion:The increase of NLR before treatment suggests a poor prognosis in DLBCL patients.
作者
傅郗雨菁
杨顺娥
FU Xiyujing;YANG Shun'e(The Third Clinical Medical College of Xinjiang Medical University,Xinjiang Urumqi 830002,China;Department of Lymphoma Division,Cancer Hospital Affiliated to Xinjiang Medical University,Xinjiang Urumqi 830002,China)
出处
《现代肿瘤医学》
CAS
北大核心
2022年第22期4162-4166,共5页
Journal of Modern Oncology
